Charles River Laboratories International, Inc. (CRL) has reported Q1 2024 earnings, with revenue surpassing expectations but EPS trailing. CRL's price target has been reduced to $270.00 by analysts at Robert W. Baird. Various investment groups are changing their stake in CRL, with some reducing and some increasing their holdings. CRL has provided an FY 2024 earnings guidance, despite having some shortcomings. Several firms are maintaining significant stock positions in the firm, despite some selling their shares. CRL continues to receive a 'Moderate Buy' recommendation, with various new insights being uncovered. CRL is showcasing technology-driven capabilities and has published a 2024 Earnings Preview. It is making great strides in reducing reliance on animal testing and increasing renewable electricity usage globally. There are also discussions about collaborations, partnerships and agreements to develop new therapies and expedite research. Operational results from different quarters have been announced with CRL continuing to perform well, exceeding estimates at times. New alliances are being formed, as CRL extends its gene therapy offering and releases new products. Nevertheless, there are concerns and legal investigations concerning the directors and officers of the firm.
Charles River Laboratories International CRL News Analytics from Mon, 10 Jul 2023 07:00:00 GMT to Sat, 11 May 2024 22:56:52 GMT -
Rating 0
- Innovation 5
- Information 7
- Rumor 4
